Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt N/A
BMY's Cash to Debt is ranked higher than
82% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.63 vs. BMY: N/A )
Ranked among companies with meaningful Cash to Debt only.
BMY' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: 0.88 Max: 2.26
Current: N/A
0.32
2.26
Equity to Asset 0.47
BMY's Equity to Asset is ranked lower than
72% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. BMY: 0.47 )
Ranked among companies with meaningful Equity to Asset only.
BMY' s Equity to Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.45 Max: 0.55
Current: 0.47
0.35
0.55
Interest Coverage 10.27
BMY's Interest Coverage is ranked lower than
75% of the 470 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 123.58 vs. BMY: 10.27 )
Ranked among companies with meaningful Interest Coverage only.
BMY' s Interest Coverage Range Over the Past 10 Years
Min: 4.67  Med: 14.09 Max: 45.84
Current: 10.27
4.67
45.84
F-Score: 7
Z-Score: 6.03
M-Score: -2.07
WACC vs ROIC
9.34%
8.03%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 11.41
BMY's Operating margin (%) is ranked higher than
58% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.82 vs. BMY: 11.41 )
Ranked among companies with meaningful Operating margin (%) only.
BMY' s Operating margin (%) Range Over the Past 10 Years
Min: 12.83  Med: 19.41 Max: 31.29
Current: 11.41
12.83
31.29
Net-margin (%) 9.81
BMY's Net-margin (%) is ranked higher than
64% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.45 vs. BMY: 9.81 )
Ranked among companies with meaningful Net-margin (%) only.
BMY' s Net-margin (%) Range Over the Past 10 Years
Min: 9.19  Med: 15.78 Max: 56.42
Current: 9.81
9.19
56.42
ROE (%) 12.86
BMY's ROE (%) is ranked higher than
68% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. BMY: 12.86 )
Ranked among companies with meaningful ROE (%) only.
BMY' s ROE (%) Range Over the Past 10 Years
Min: 13.25  Med: 20.69 Max: 78.36
Current: 12.86
13.25
78.36
ROA (%) 5.92
BMY's ROA (%) is ranked higher than
61% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.67 vs. BMY: 5.92 )
Ranked among companies with meaningful ROA (%) only.
BMY' s ROA (%) Range Over the Past 10 Years
Min: 5.54  Med: 9.18 Max: 35.08
Current: 5.92
5.54
35.08
ROC (Joel Greenblatt) (%) 59.68
BMY's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.76 vs. BMY: 59.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BMY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 45.71  Med: 71.78 Max: 155.17
Current: 59.68
45.71
155.17
Revenue Growth (3Y)(%) -8.40
BMY's Revenue Growth (3Y)(%) is ranked lower than
83% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. BMY: -8.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BMY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.4  Med: 2.40 Max: 11.8
Current: -8.4
-8.4
11.8
EBITDA Growth (3Y)(%) -26.00
BMY's EBITDA Growth (3Y)(%) is ranked lower than
86% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. BMY: -26.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BMY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -26  Med: -0.40 Max: 21.5
Current: -26
-26
21.5
EPS Growth (3Y)(%) -17.80
BMY's EPS Growth (3Y)(%) is ranked lower than
76% of the 487 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. BMY: -17.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BMY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.9  Med: -3.45 Max: 30.7
Current: -17.8
-22.9
30.7
» BMY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

BMY Guru Trades in Q1 2015

Paul Tudor Jones 164,515 sh (New)
Louis Moore Bacon 60,000 sh (New)
Steven Cohen 620,900 sh (+151.99%)
Jim Simons 474,100 sh (+58.83%)
Vanguard Health Care Fund 42,902,031 sh (+9.85%)
Ken Fisher 32,441 sh (+5.54%)
Pioneer Investments 87,155 sh (+3.18%)
Jeff Auxier 5,043 sh (unchged)
Ruane Cunniff 3,670 sh (unchged)
Paul Tudor Jones 350,000 sh (unchged)
First Eagle Investment 14,492 sh (unchged)
Kahn Brothers 28,400 sh (unchged)
Ronald Muhlenkamp 212,170 sh (-0.06%)
Mairs and Power 293,770 sh (-0.43%)
Mario Gabelli 704,425 sh (-0.75%)
Dodge & Cox 87,828 sh (-3.52%)
T Rowe Price Equity Income Fund 5,814,800 sh (-7.18%)
Murray Stahl 56,017 sh (-10.83%)
Jeremy Grantham 8,110 sh (-24.64%)
» More
Q2 2015

BMY Guru Trades in Q2 2015

RS Investment Management 351,060 sh (New)
Steven Cohen 849,200 sh (+36.77%)
Ken Fisher 34,636 sh (+6.77%)
Vanguard Health Care Fund 43,718,751 sh (+1.90%)
Kahn Brothers 28,800 sh (+1.41%)
Jeff Auxier 5,043 sh (unchged)
Ruane Cunniff 3,670 sh (unchged)
Steven Cohen 500,000 sh (unchged)
T Rowe Price Equity Income Fund 5,814,800 sh (unchged)
Louis Moore Bacon Sold Out
Jim Simons Sold Out
Ronald Muhlenkamp 211,620 sh (-0.26%)
Murray Stahl 55,867 sh (-0.27%)
Pioneer Investments 86,650 sh (-0.58%)
Mario Gabelli 678,636 sh (-3.66%)
Mairs and Power 282,983 sh (-3.67%)
Dodge & Cox 80,928 sh (-7.86%)
First Eagle Investment 13,325 sh (-8.05%)
Jeremy Grantham 7,410 sh (-8.63%)
Paul Tudor Jones 25,871 sh (-84.27%)
» More
Q3 2015

BMY Guru Trades in Q3 2015

Ray Dalio 19,528 sh (New)
John Burbank 401,253 sh (New)
Joel Greenblatt 21,863 sh (New)
George Soros 5,000 sh (New)
Signature Select Canadian Fund 258,600 sh (New)
Ken Fisher 61,180 sh (+76.64%)
RS Investment Management 522,650 sh (+48.88%)
Steven Cohen 1,099,000 sh (+29.42%)
Murray Stahl 58,442 sh (+4.61%)
Vanguard Health Care Fund 45,346,149 sh (+3.72%)
Mairs and Power 284,574 sh (+0.56%)
Pioneer Investments 86,973 sh (+0.37%)
Ronald Muhlenkamp 211,750 sh (+0.06%)
First Eagle Investment 13,325 sh (unchged)
Kahn Brothers 28,800 sh (unchged)
Ruane Cunniff 3,670 sh (unchged)
Steven Cohen 1,100,000 sh (unchged)
Jeff Auxier 5,043 sh (unchged)
Dodge & Cox 79,928 sh (-1.24%)
Mario Gabelli 651,417 sh (-4.01%)
T Rowe Price Equity Income Fund 5,512,700 sh (-5.20%)
Jeremy Grantham 5,400 sh (-27.13%)
Paul Tudor Jones 16,320 sh (-36.92%)
» More
Q4 2015

BMY Guru Trades in Q4 2015

Ken Fisher 134,800 sh (+120.33%)
Vanguard Health Care Fund 46,232,449 sh (+1.95%)
Ronald Muhlenkamp 211,755 sh (unchged)
Mario Gabelli 639,355 sh (-1.85%)
Jeff Auxier 4,943 sh (-1.98%)
Kahn Brothers 28,050 sh (-2.60%)
T Rowe Price Equity Income Fund 4,520,000 sh (-18.01%)
» More
» Details

Insider Trades

Latest Guru Trades with BMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Bristol-Myers Squibb Company

SymbolPriceYieldDescription
BMYMP1093.000.18$2.00 Convertible Preferred Stock

Guru Investment Theses on Bristol-Myers Squibb Company

Vanguard Health Care Fund Comments on Bristol-Myers Squibb Company - Mar 27, 2015

We increased our position in this biopharmaceutical company. We see its immuno-oncology franchise as a transformative driver in the years ahead and believe the market does not fully recognize the magnitude of the company’s potential in this area. Bristol-Myers Squibb (BMY) was the fund’s largest holding at the end of the period.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Bristol-Myers Squibb Company

5 Top Stocks of the Outperforming Vanguard Health Care Fund The fund has beat the index on a one-, five- and 10-year basis and since inception
The Vanguard Health Care Fund (Trades, Portfolio) (VGHCX)’s selection of stocks from a variety of areas within the foreign and domestic health care sector has resulted in a fantastic performance record. Read more...
Vanguard Adds to Four of Its Largest Stakes
It isn’t surprising that nearly 95% of Vanguard Health Care Fund (Trades, Portfolio)’s holdings are related to health care, drug manufacturing and medical technology. But there has been some jockeying for position within the Fund’s portfolio in the early months of 2015. Read more...
Vanguard Health Care Fund Comments on Bristol-Myers Squibb Company
We increased our position in this biopharmaceutical company. We see its immuno-oncology franchise as a transformative driver in the years ahead and believe the market does not fully recognize the magnitude of the company’s potential in this area. Bristol-Myers Squibb (BMY) was the fund’s largest holding at the end of the period. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 57.79
BMY's P/E(ttm) is ranked lower than
79% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.80 vs. BMY: 57.79 )
Ranked among companies with meaningful P/E(ttm) only.
BMY' s P/E(ttm) Range Over the Past 10 Years
Min: 4.05  Med: 20.42 Max: 65.32
Current: 57.79
4.05
65.32
Forward P/E 19.27
BMY's Forward P/E is ranked lower than
59% of the 403 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.75 vs. BMY: 19.27 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 57.69
BMY's PE(NRI) is ranked lower than
77% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.83 vs. BMY: 57.69 )
Ranked among companies with meaningful PE(NRI) only.
BMY' s PE(NRI) Range Over the Past 10 Years
Min: 12.26  Med: 21.00 Max: 65.2
Current: 57.69
12.26
65.2
P/B 6.75
BMY's P/B is ranked lower than
95% of the 936 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.38 vs. BMY: 6.75 )
Ranked among companies with meaningful P/B only.
BMY' s P/B Range Over the Past 10 Years
Min: 2.46  Med: 4.15 Max: 7.64
Current: 6.75
2.46
7.64
P/S 6.20
BMY's P/S is ranked lower than
87% of the 937 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.68 vs. BMY: 6.20 )
Ranked among companies with meaningful P/S only.
BMY' s P/S Range Over the Past 10 Years
Min: 2.29  Med: 3.57 Max: 9.63
Current: 6.2
2.29
9.63
PFCF 96.95
BMY's PFCF is ranked lower than
84% of the 465 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.80 vs. BMY: 96.95 )
Ranked among companies with meaningful PFCF only.
BMY' s PFCF Range Over the Past 10 Years
Min: 7.44  Med: 20.07 Max: 141.78
Current: 96.95
7.44
141.78
POCF 57.66
BMY's POCF is ranked lower than
78% of the 631 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.19 vs. BMY: 57.66 )
Ranked among companies with meaningful POCF only.
BMY' s POCF Range Over the Past 10 Years
Min: 6.95  Med: 14.69 Max: 65.2
Current: 57.66
6.95
65.2
EV-to-EBIT 39.55
BMY's EV-to-EBIT is ranked lower than
81% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.51 vs. BMY: 39.55 )
Ranked among companies with meaningful EV-to-EBIT only.
BMY' s EV-to-EBIT Range Over the Past 10 Years
Min: 8  Med: 13.30 Max: 895.3
Current: 39.55
8
895.3
EV-to-EBITDA 35.49
BMY's EV-to-EBITDA is ranked lower than
82% of the 847 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.31 vs. BMY: 35.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
BMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.2  Med: 11.40 Max: 120.7
Current: 35.49
7.2
120.7
Shiller P/E 29.64
BMY's Shiller P/E is ranked higher than
66% of the 170 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.66 vs. BMY: 29.64 )
Ranked among companies with meaningful Shiller P/E only.
BMY' s Shiller P/E Range Over the Past 10 Years
Min: 8.99  Med: 14.78 Max: 33.71
Current: 29.64
8.99
33.71
Current Ratio 1.81
BMY's Current Ratio is ranked lower than
59% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.27 vs. BMY: 1.81 )
Ranked among companies with meaningful Current Ratio only.
BMY' s Current Ratio Range Over the Past 10 Years
Min: 1.13  Med: 1.61 Max: 2.32
Current: 1.81
1.13
2.32
Quick Ratio 1.65
BMY's Quick Ratio is ranked higher than
50% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. BMY: 1.65 )
Ranked among companies with meaningful Quick Ratio only.
BMY' s Quick Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.33 Max: 2.07
Current: 1.65
0.93
2.07
Days Inventory 108.87
BMY's Days Inventory is ranked higher than
55% of the 643 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.46 vs. BMY: 108.87 )
Ranked among companies with meaningful Days Inventory only.
BMY' s Days Inventory Range Over the Past 10 Years
Min: 84.37  Med: 124.11 Max: 141.93
Current: 108.87
84.37
141.93
Days Sales Outstanding 59.82
BMY's Days Sales Outstanding is ranked higher than
63% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.01 vs. BMY: 59.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.38  Med: 64.75 Max: 79.99
Current: 59.82
35.38
79.99
Days Payable 116.62
BMY's Days Payable is ranked higher than
72% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.59 vs. BMY: 116.62 )
Ranked among companies with meaningful Days Payable only.
BMY' s Days Payable Range Over the Past 10 Years
Min: 78.8  Med: 129.33 Max: 230.86
Current: 116.62
78.8
230.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.43
BMY's Dividend Yield is ranked higher than
74% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. BMY: 2.43 )
Ranked among companies with meaningful Dividend Yield only.
BMY' s Dividend Yield Range Over the Past 10 Years
Min: 2.12  Med: 4.32 Max: 7.07
Current: 2.43
2.12
7.07
Dividend Payout 1.40
BMY's Dividend Payout is ranked higher than
68% of the 419 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. BMY: 1.40 )
Ranked among companies with meaningful Dividend Payout only.
BMY' s Dividend Payout Range Over the Past 10 Years
Min: 0.08  Med: 0.63 Max: 46.25
Current: 1.4
0.08
46.25
Dividend Growth (3y) 2.90
BMY's Dividend Growth (3y) is ranked lower than
60% of the 280 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. BMY: 2.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
BMY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 3.30 Max: 11.4
Current: 2.9
0
11.4
Forward Dividend Yield 2.49
BMY's Forward Dividend Yield is ranked higher than
70% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. BMY: 2.49 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.82
BMY's Yield on cost (5-Year) is ranked higher than
70% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.86 vs. BMY: 2.82 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BMY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.46  Med: 5.01 Max: 8.2
Current: 2.82
2.46
8.2
3-Year Average Share Buyback Ratio 0.90
BMY's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 462 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.90 vs. BMY: 0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BMY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.3  Med: 0.60 Max: 5.1
Current: 0.9
-0.3
5.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 15.46
BMY's Price/Tangible Book is ranked lower than
90% of the 909 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.72 vs. BMY: 15.46 )
Ranked among companies with meaningful Price/Tangible Book only.
BMY' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.91  Med: 13.23 Max: 53.3
Current: 15.46
4.91
53.3
Price/Projected FCF 2.15
BMY's Price/Projected FCF is ranked higher than
53% of the 548 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.16 vs. BMY: 2.15 )
Ranked among companies with meaningful Price/Projected FCF only.
BMY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.13  Med: 1.58 Max: 4.53
Current: 2.15
1.13
4.53
Price/Median PS Value 2.33
BMY's Price/Median PS Value is ranked lower than
84% of the 924 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. BMY: 2.33 )
Ranked among companies with meaningful Price/Median PS Value only.
BMY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.72  Med: 1.13 Max: 3.19
Current: 2.33
0.72
3.19
Price/Graham Number 6.29
BMY's Price/Graham Number is ranked lower than
90% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.18 vs. BMY: 6.29 )
Ranked among companies with meaningful Price/Graham Number only.
BMY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.75  Med: 4.00 Max: 10.63
Current: 6.29
1.75
10.63
Earnings Yield (Greenblatt) (%) 2.55
BMY's Earnings Yield (Greenblatt) (%) is ranked lower than
54% of the 723 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. BMY: 2.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BMY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 7.50 Max: 12.5
Current: 2.55
0.1
12.5
Forward Rate of Return (Yacktman) (%) -11.58
BMY's Forward Rate of Return (Yacktman) (%) is ranked lower than
81% of the 325 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.77 vs. BMY: -11.58 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BMY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -14.6  Med: 6.10 Max: 26.7
Current: -11.58
-14.6
26.7

More Statistics

Revenue(Mil) $16560
EPS $ 0.97
Beta1.07
Short Percentage of Float1.38%
52-Week Range $51.82 - 70.87
Shares Outstanding(Mil)1668.29

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 17,476 19,963 22,491
EPS($) 2.41 3.17 4.07
EPS without NRI($) 2.41 3.17 4.07

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:BMY.Argentina, BMYB34.Brazil, BRM.Germany, BMY.Mexico, BMY.Switzerland, 0R1F.UK, BMYMP.USA,
Bristol-Myers Squibb Co is a Delaware corporation and was incorporated in August 1933 under the name Bristol-Myers Company. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. It is a biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in one segment: Biopharmaceuticals. The Company's pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes called 'biologics'. These products are sold mainly to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. The Company's products include, Plavix, Avapro, Eliquis, Reyataz, Sustiva Franchise, Baraclude, Sprycel, Yervoy, Orencia among others. The Company promotes its products to healthcare providers such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs) and government agencies. The Company also markets directly to consumers in the U.S. through direct-to-consumer print, radio and television and digital advertising and promotion. The markets in which the Company competes are generally broad-based and competitive. The Company competes with other research-based drug companies, research companies and generic drug manufacturers. The Company is subject to regulation by regional, country, state and local agencies.
» More Articles for BMY

Headlines

Articles On GuruFocus.com
10 Fund Managers Are Totally Wrong on GlaxoSmithKline Jan 26 2016 
5 Top Stocks of the Outperforming Vanguard Health Care Fund Dec 28 2015 
Designing the Appropriate Common Stock Retirement Portfolio: Stock Selection Options Part 1 Sep 14 2015 
Weekly Insider Sells Highlight: IMS, NOW, BMY, EA Aug 11 2015 
Will Bill Ackman Go After Express Scripts Next? Jun 30 2015 
Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
Abbvie Inc. Dividend Stock Analysis May 26 2015 
Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio May 07 2015 
Vanguard Adds to Four of Its Largest Stakes May 04 2015 

More From Other Websites
Short Sellers Increase Bets in Major Pharma Feb 10 2016
Bristol-Myers Squibb Is Ready to Lead Again: Must-See Charts Feb 09 2016
Bristol-Myers' Daklinza-Sovaldi Label Expanded by the FDA Feb 08 2016
Where is Ronald Reagan When You Need Him? Feb 08 2016
U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional... Feb 05 2016
Growth, Factors at Play - Analyst Notes on General Electric, Dow Chemical, Bristol-Myers Squibb and... Feb 04 2016
Bristol-Myers Squibb to Take Part in Leerink Swann Global Healthcare Conference Feb 03 2016
Merck gives cautious 2016 outlook as sales of top medicines lag Feb 03 2016
Pfizer earnings fall but tops Street 4Q forecasts Feb 02 2016
Pfizer earnings fall but tops Street 4Q forecasts Feb 02 2016
Bristol-Myers Squibb Co. Earnings Analysis: Q4, 2015 By the Numbers Feb 02 2016
Bristol-Myers Squibb Foundation Awards Eight Grants Totaling Nearly $11.5M to Make Lung and Skin... Feb 01 2016
Bristol-Myers Squibb Foundation Awards Eight Grants Totaling Nearly $11.5M to Make Lung and Skin... Feb 01 2016
Technical Pointers on Drug Manufacturers - Major Stocks -- Bristol-Myers Squibb, Eli Lilly,... Feb 01 2016
Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and... Feb 01 2016
Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and... Feb 01 2016
Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and... Feb 01 2016
Adversity Creates Opportunity Feb 01 2016
Bristol-Myers' Daklinza-Sovaldi Label Expanded in the EU Jan 29 2016
What Will Cure Bristol-Myers Squibb? Jan 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK